Journal
EXPERIMENTAL BRAIN RESEARCH
Volume 230, Issue 4, Pages 555-568Publisher
SPRINGER
DOI: 10.1007/s00221-013-3694-y
Keywords
Serotonin; 5-HT7 receptor; GPCR
Categories
Funding
- Janssen Pharmaceutica N.V., Beerse
- IWT (Instituut voor de aanmoediging van innovatie door wetenschap en technologie in Vlaanderen) project [990173]
- FWO (Fonds voor wetenschappelijk onderzoek Vlaanderen
- KVC has a postdoctoral FWO scholarship)
- Norwegian Research Council
- The Novo Nordisk Foundation
Ask authors/readers for more resources
Like most neurotransmitters, serotonin possesses a simple structure. However, the pharmacological consequences are more complex and diverse. Serotonin is involved in numerous functions in the human body including the control of appetite, sleep, memory and learning, temperature regulation, mood, behavior, cardiovascular function, muscle contraction, endocrine regulation, and depression. Low levels of serotonin may be associated with several disorders, namely increase in aggressive and angry behaviors, clinical depression, Parkinson's disease, obsessive-compulsive disorder, eating disorders, migraine, irritable bowel syndrome, tinnitus, and bipolar disease. These effects are mediated via different serotonin (5-HT) receptors. In this review, we will focus on the last discovered member of this serotonin receptor family, the 5-HT7 receptor. This receptor belongs to the G protein-coupled receptor superfamily and was cloned two decades ago. Later, different splice variants were described but no major functional differences have been described so far. All 5-HT7 receptor variants are coupled to G alpha(s) proteins and stimulate cAMP formation. Recently, several interacting proteins have been reported, which can influence receptor signaling and trafficking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available